Author: yarone

Categories

• News and Events
  • Events
  • News
• Publications
  • CM-24
  • more about CM-24
  • more about NT-219
  • NT-219

Posts

• Drug Discovery World article on NT219 poster publication on AACR23: “New drug could help overcome tumour resistance to treatment”
• NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy
• Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
• Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.
• Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
• Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
• Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
• Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
• Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
• CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells